- Global Pharma News & Resources

Global Targeted Sequencing Market Report 2022 to 2032: Featuring MedGenome, Novogene, PacBio. Paragon Genomics and PerkinElmer Among Others -

DUBLIN--(BUSINESS WIRE)--The "Targeted Sequencing Market - A Global and Regional Analysis: Focus on Product Type, Target Enrichment Method, Type of Target Capture, Application, End User, and Region Analysis - Analysis and Forecast, 2022-2032" report has been added to's offering.

The global targeted sequencing market is projected to reach $10,976.1 million by 2032 from $3,198.8 million in 2022, growing at a CAGR of 13.12% during the forecast period 2022-2032.

The growth in the global targeted sequencing market is expected to be driven by the increased use of targeted sequencing in clinical laboratories and diagnostic applications, especially in cancer research.

Targeted sequencing is a cost-effective and rapid way to detect novel and known variants in selected genetic or genomic regions. There are several different methods of DNA/RNA sequencing depending on the scale of the region being sequenced.

Next-generation sequencing (NGS) is the most used method for targeted sequencing, which offers good scalability, speed, and resolution to evaluate the targeted regions of interest. Other methods include sanger sequencing and CRISPR.

The major advantage of targeted sequencing as compared to whole genome sequencing is the smaller and more manageable data sets created, which are significantly easier to analyze.

Targeted next-generation sequencing focuses on specific genomic areas of interest, which is ideal for examining specific pathways or targeted resequencing. Furthermore, it is more rapid and cost-effective as compared to whole genome sequencing and allows deeper sequencing. This is a powerful and especially sensitive method of identifying gene mutations and variants, including rare variants.

Recent Developments in Global Targeted Sequencing Market

  • In August 2022, QIAGEN N.V. launched its QIAseq targeted DNA pro panels and the QIAseq UPXome RNA library kit as an expansion of its next-generation sequencing (NGS) portfolio. Both these launches lead to the growth of the company's sequencing product portfolio.
  • In September 2022, BGI Group (MGI Tech Co., Ltd.) launched its DNBSEQ-G99, which is a mid to low-range throughput sequencer. This makes this sequencer especially suitable for targeted gene sequencing, small gene sequencing, and high and rapid-quality data output.
  • In June 2022, Agilent Technologies, Inc. announced its collaboration with the Amazon Elastic Compute Cloud (Amazon EC2) G5g powered by Amazon Web Services (AWS) Graviton2 processors. The NVIDIA T4G Tensor Core GPUs, combined with NVIDIA Clara Parabricks' advanced genomics capabilities, improved Agilent Technologies, Inc.'s cloud-native Alissa Reporter software. This collaboration is expected to streamline the company's SureSelect family NGS assays, which comprise a wide range of custom and catalog panels.
  • In June 2022, Danaher. (Integrated DNA Technologies, Inc.) made an agreement with Beckman Coulter, Inc. Life Sciences for the distribution of its Biomek NGenius Next Generation Sequencing Library Prep System. This deal helped make high-performance NGS solutions more accessible to laboratories.

Market Dynamics


  • Rising Need for Sequencing at Greater Depth
  • Lower Cost and Data Burden of Targeted Sequencing When Compared to Whole Genome Sequencing
  • Increase in Cancer Prevalence


  • Lack of Knowledge About New Genes and Biomarkers
  • Lack of High Complexity Genomic Testing Centers in High Potential Markets


  • Increasing Use in Clinical Research and Trials for Better Disease Pathogenesis and/or Clinical Relevance
  • Rising Adoption of Targeted Sequencing in Targeted Therapeutics

Companies Mentioned

  • Agilent Technologies, Inc.
  • Azenta US, Inc. (GENEWIZ)
  • BGI Group (MGI Tech Co. Ltd.)
  • CD Genomics
  • Daicel Corporation (Daicel Arbor Biosciences)
  • Danaher. (Integrated DNA Technologies, Inc.)
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • LGC Limited (LGC Biosearch Technologies)
  • MedGenome
  • Novogene Co. Ltd.
  • PacBio
  • Paragon Genomics, Inc.
  • PerkinElmer Inc.
  • Psomagen
  • Sage Science, Inc.
  • Takara Bio Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience
  • Zymo Research Corporation

Market Segmentation

Segmentation 1: by Product Type

  • Instruments
  • Kits/Panels and Assays
  • Services
  • Other Product Types

Segmentation 2: by Target Enrichment Method

  • Hybridization Capture
  • Amplicon Sequencing
  • Other Target Enrichment Methods

Segmentation 3: by Type of Target Capture

  • Targeted DNA Sequencing
  • Targeted RNA Sequencing
  • Other Types of Target Capture

Segmentation 4: by Application

  • Oncology
  • Reproductive Health
  • Hereditary Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Cardiovascular Diseases
  • Rare Diseases
  • Other Applications

Segmentation 5: by End User

  • Diagnostic and Clinical Laboratories
  • Academic and Research Institutions
  • Pharmaceutical and Biotech Companies
  • Other End Users

Segmentation 6: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World (RoW)

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 13-Feb-2023